组合生物标志物预测HER2阳性乳腺癌新辅助拉帕替尼联合曲妥珠单抗、无化疗方案的病理完全缓解
研究评估基线HER2扩增水平和PI3K通路状态与HER2阳性乳腺癌患者接受新辅助拉帕替尼联合曲妥珠单抗(ER阳性者加内分泌治疗)后病理完全缓解(pCR)的关系。56例中23%达到pCR;HER2比值≥4和/或拷贝数≥10且PI3K通路完整的患者pCR率较高,而HER2比值<4和/或拷贝数<10者无一达到pCR。作者认为高HER2扩增且PI3K通路完整的亚型对无化疗的HER2靶向治疗特别敏感,该组合标志物需验证以筛选可免化疗的患者。
要点
- 56例中13例(23%)达到pCR。
- HER2比值<4和/或拷贝数<10的11例均未达pCR;HER2比值≥4和/或拷贝数≥10的45例中13例(29%)达pCR(P=0.0513)。
- PI3K通路完整者18例中7例(39%)达pCR,PI3K通路改变者23例中1例(4%)达pCR(P=0.0133)。
核心结论
- 研究提示存在一种HER2高扩增且PI3K通路完整的乳腺癌临床亚型,对无化疗的HER2靶向治疗特别敏感。
- HER2 FISH比值联合PI3K通路状态需验证,以识别可能接受无化疗HER2靶向治疗的患者。
研究设计与样本
- TBCRC006研究(NCT00548184)中接受新辅助拉帕替尼联合曲妥珠单抗(ER阳性肿瘤加内分泌治疗)患者的基线HER2阳性肿瘤,在中心实验室通过FISH评估HER2扩增(n=56)。
- 41例肿瘤可获得HER2拷贝数、FISH比值及PI3K通路状态(PIK3CA突变或免疫组化PTEN水平)。
- 结果与pCR(乳腺无残留浸润性肿瘤)进行相关性分析。
主要发现
- 56例患者中13例(23%)达到pCR。
- HER2比值<4和/或拷贝数<10的11例患者均未达到pCR,而HER2比值≥4和/或拷贝数≥10的45例患者中13例(29%)达到pCR(P=0.0513)。
- PTEN高表达或PIK3CA野生型(PI3K通路完整)的18例患者中7例(39%)达到pCR,而PI3K通路改变的23例患者中1例(4%)达到pCR(P=0.0133)。
- HER2比值≥4且PI3K通路完整的16例患者中7例(44%)达到pCR,而不符合这些标准的25例患者中仅1例(4%)达到pCR(P=0.0031)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出该组合标志物需验证以识别可能接受无化疗HER2靶向治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER2 amplification levels and PI3K pathway activation are key determinants of response to HER2-targeted treatments without chemotherapy. PATIENTS AND METHODS: Baseline HER2+ tumors from patients treated with neoadjuvant lapatinib plus trastuzumab [with endocrine therapy for estrogen receptor (ER)+ tumors] in TBCRC006 (NCT00548184) were evaluated in a central laboratory for HER2 amplification by fluorescence in situ hybridization (FISH) (n = 56). HER2 copy number (CN) and FISH ratios, and PI3K pathway status, defined by PIK3CA mutations or PTEN levels by immunohistochemistry were available for 41 tumors. Results were correlated with pathologic complete response (pCR; no residual invasive tumor in breast). RESULTS: Thirteen of the 56 patients (23%) achieved pCR. None of the 11 patients with HER2 ratio <4 and/or CN <10 achieved pCR, whereas 13/45 patients (29%) with HER2 ratio ≥4 and/or CN ≥10 attained pCR (P = 0.0513). Of the 18 patients with tumors expressing high PTEN or wild-type (WT) PIK3CA (intact PI3K pathway), 7 (39%) achieved pCR, compared with 1/23 (4%) with PI3K pathway alterations (P = 0.0133). Seven of the 16 patients (44%) with HER2 ratio ≥4 and intact PI3K pathway achieved pCR, whereas only 1/25 (4%) patients not meeting these criteria achieved pCR (P = 0.0031). CONCLUSIONS: Our findings suggest that there is a clinical subtype in breast cancer with high HER2 amplification and intact PI3K pathway that is especially sensitive to HER2-targeted therapies without chemotherapy. A combination of HER2 FISH ratio and PI3K pathway status warrants validation to identify patients who may be treated with HER2-targeted therapy without chemotherapy.
引用
- Veeraraghavan J, De Angelis C, Mao R, et al. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019. PMID: 30903140. doi:10.1093/annonc/mdz076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。